Hostname: page-component-586b7cd67f-rcrh6 Total loading time: 0 Render date: 2024-11-27T02:43:28.799Z Has data issue: false hasContentIssue false

2nd generation antipsychotics for refractory generalized anxiety disorder

Published online by Cambridge University Press:  16 April 2020

V. Psarra
Affiliation:
Psychiatric Hospital of Attiki Dafni, Athens, Greece
N. Dimopoulos
Affiliation:
Mental Clinic Asklipieion, Athens, Greece
C. Mitsonis
Affiliation:
Psychiatric Hospital of Attiki Dafni, Athens, Greece

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Benzodiazepines and antidepressants are frequently used for the treatment of anxiety disorders, nevertheless low rates of remission and high rates of nonresponse are reported with their use. Fourty to 70% of patients with anxiety disorders fail to respond and more remain partly symptomatic after treatment, therefore there is a need for novel therapeutic strategies for refractory patients.

A small number of studies have been conducted in order to investigate the efficacy of 2nd generation antipsychotics for generalized anxiety disorder (GAD). Risperidone, olanzapine, aripiprazole, quetiapine and ziprasidone have proven to be effective and safe for the treatment of generalized anxiety disorder, either as augmentors of selective serotonine reuptake inhibitors (SSRI's) or as monotherapy.

However, definite conclusions cannot be drawn based on the small number of studies, the fact that they were mostly open-label and had small sample sizes. The efficacy and safety of 2nd generation antipsychotics in GAD needs to be further investigated with randomized, double-blind, placebo controlled trials.

Type
Poster Session 1: Antipsychotic Medications
Copyright
Copyright © European Psychiatric Association 2007
Submit a response

Comments

No Comments have been published for this article.